Mostra i principali dati dell'item
A BAFF Receptor His159Tyr Mutation in Sjögren’s Syndrome-Related Lymphoproliferation
| dc.creator | Papageorgiou A., Mavragani C.P., Nezos A., Zintzaras E., Quartuccio L., De Vita S., Koutsilieris M., Tzioufas A.G., Moutsopoulos H.M., Voulgarelis M. | en |
| dc.date.accessioned | 2023-01-31T09:42:54Z | |
| dc.date.available | 2023-01-31T09:42:54Z | |
| dc.date.issued | 2015 | |
| dc.identifier | 10.1002/ART.39231 | |
| dc.identifier.issn | 23265191 | |
| dc.identifier.uri | http://hdl.handle.net/11615/77655 | |
| dc.description.abstract | Objective. To study the prevalence, clinical associations, and functional implications of the His159Tyr mutation of the BAFF receptor (BAFF-R) in patients with Sjögren’s syndrome (SS). Methods. The BAFF-R His159Tyr mutation was evaluated using polymerase chain reaction (PCR)-based assays in 247 patients with SS (of whom 70 had SS complicated by lymphoma [SS-lymphoma]), 145 with systemic lupus erythematosus (SLE), and 101 with rheumatoid arthritis (RA), as well as 180 healthy controls. Real-time PCR and Western blotting were performed for the quanti fication of both NF-kB1 and NF-kB2 messenger RNA (mRNA) transcript and protein levels in isolated B cells from patients with SS-lymphoma carrying the mutation (SS-lymphoma-BAFF-RHis159Tyr-derived B cells) compared to B cells from patients with SS-lymphoma who were not carriers of the mutation and healthy controls. Results. Both the SS-lymphoma and SS-nonlymphoma patient subgroups exhibited significantly higher frequencies of the His159Tyr BAFF-R mutation compared to healthy controls (8.6% of SS-lymphoma patients and 6.2% of SS-nonlymphoma patients versus 1.7% of healthy controls; P = 0.02 and P = 0.04, respectively). The corresponding frequencies of the His159Tyr BAFF-R mutation in SLE and RA patients were 3.5% and 3%, respectively. Of interest, 71.4% of the SS patients with mucosa-associated lymphoid tissue (MALT) lymphoma who were between the ages of 31 and 40 years at disease onset were mutation carriers. The generalized odds ratio for the development of SS-related MALT lymphoma in the younger age at onset (age <40 years) group in the presence of the BAFF-R mutation was 6.1 (95% confidence interval 2.0-18.7) (P < 0.01). Expression of NF-kB at both the mRNA and protein level was up-regulated in SS-lymphoma-BAFF-RHis159Tyr-derived B cells. Conclusion. This study identifies an increased prevalence of the BAFF-R His159Tyr mutation in patients with SS, particularly in those with SS complicated by MALT lymphoma whose disease onset occurred at a younger age. BAFF-RHis159Tyr-mediated activation of the alternate NF-kB pathway might contribute to the pathogenesis of SS-related lymphoproliferative disease. © 2015, American College of Rheumatology. | en |
| dc.language.iso | en | en |
| dc.source | Arthritis and Rheumatology | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84988864510&doi=10.1002%2fART.39231&partnerID=40&md5=16df07d98a53659f8f5a6de0a5921ba7 | |
| dc.subject | B cell activating factor receptor | en |
| dc.subject | immunoglobulin enhancer binding protein | en |
| dc.subject | adult | en |
| dc.subject | aged | en |
| dc.subject | Arthritis, Rheumatoid | en |
| dc.subject | case control study | en |
| dc.subject | complication | en |
| dc.subject | female | en |
| dc.subject | genetic predisposition | en |
| dc.subject | genetics | en |
| dc.subject | heterozygote | en |
| dc.subject | human | en |
| dc.subject | Lupus Erythematosus, Systemic | en |
| dc.subject | Lymphoproliferative Disorders | en |
| dc.subject | male | en |
| dc.subject | marginal zone lymphoma | en |
| dc.subject | middle aged | en |
| dc.subject | mutation | en |
| dc.subject | physiology | en |
| dc.subject | prevalence | en |
| dc.subject | signal transduction | en |
| dc.subject | Sjogren's Syndrome | en |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Arthritis, Rheumatoid | en |
| dc.subject | B-Cell Activation Factor Receptor | en |
| dc.subject | Case-Control Studies | en |
| dc.subject | Female | en |
| dc.subject | Genetic Predisposition to Disease | en |
| dc.subject | Heterozygote | en |
| dc.subject | Humans | en |
| dc.subject | Lupus Erythematosus, Systemic | en |
| dc.subject | Lymphoma, B-Cell, Marginal Zone | en |
| dc.subject | Lymphoproliferative Disorders | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Mutation | en |
| dc.subject | NF-kappa B | en |
| dc.subject | Prevalence | en |
| dc.subject | Signal Transduction | en |
| dc.subject | Sjogren's Syndrome | en |
| dc.subject | John Wiley and Sons Inc | en |
| dc.title | A BAFF Receptor His159Tyr Mutation in Sjögren’s Syndrome-Related Lymphoproliferation | en |
| dc.type | journalArticle | en |
Files in questo item
| Files | Dimensione | Formato | Mostra |
|---|---|---|---|
|
Nessun files in questo item. |
|||